PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2010.42.4.2252010424225The CXCR4 Antagonist AMD3100 Has Dual Effects on Survival and Proliferation of Myeloma CellsIn VitroHa-Yon Kim, Ji-Young Hwang, Seong-Woo Kim, Hyo-Jin Lee, Hwan-Jung Yun, Samyong Kim, Deog-Yeon Johttp://www.e-crt.org/upload/pdf/crt-42-225.pdf, http://www.e-crt.org/upload/pdf/crt-42-225.pdf
European Journal of Cancer10.1016/s0959-8049(16)32734-4201669S50The CXCR4 antagonist Plerixafor (AMD3100) promotes Ewing sarcoma cell survival and migration in Ewing sarcoma cells in vitroU. Dirksen, P. Berning, C. Schaefer, J. Potratzhttps://api.elsevier.com/content/article/PII:S0959804916327344?httpAccept=text/plain, https://api.elsevier.com/content/article/PII:S0959804916327344?httpAccept=text/xml
10.21203/rs.3.rs-123530/v12020The Dual Effect of CXCR4 Antagonist AMD3100 on the Recruitment of Endogenous Endothelial Precursor Cells and Outcome of StrokeYingfeng Xia, Qiaoyuan He, Chao Li, Ruyi Yuan, Nanliang Fu, Huiyao Xiang, Jing Mou, Ming Huanghttps://www.researchsquare.com/article/rs-123530/v1, https://www.researchsquare.com/article/rs-123530/v1.html
Leukemia10.1038/leu.2008.238200822122151-2158The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiationS Tavor, M Eisenbach, J Jacob-Hirsch, T Golan, I Petit, K BenZion, S Kay, S Baron, N Amariglio, V Deutsch, E Naparstek, G Rechavihttps://www.nature.com/articles/leu2008238.pdf, https://www.nature.com/articles/leu2008238, https://www.nature.com/articles/leu2008238.pdf
Head & Neck10.1002/hed.24461201638101479-1486Antitumor effect of CXCR4 antagonist AMD3100 on the tumorigenic cell line of BHP10-3 papillary thyroid cancer cellsYoung Ho Jung, Doh Young Lee, Wonjae Cha, Bo Hae Kim, Myung-Whun Sung, Kwang Hyun Kim, Soon-Hyun Ahnhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fhed.24461, https://onlinelibrary.wiley.com/doi/full/10.1002/hed.24461
Journal of Virology10.1128/jvi.73.2.1719-1723.199919997321719-1723T134, a Small-Molecule CXCR4 Inhibitor, Has No Cross-Drug Resistance with AMD3100, a CXCR4 Antagonist with a Different StructureRieko Arakaki, Hirokazu Tamamura, Mariappan Premanathan, Kenji Kanbara, Sivasundaram Ramanan, Katsura Mochizuki, Masanori Baba, Nobutaka Fujii, Hideki Nakashimahttps://journals.asm.org/doi/pdf/10.1128/JVI.73.2.1719-1723.1999, https://journals.asm.org/doi/pdf/10.1128/JVI.73.2.1719-1723.1999
Journal of Neuro-Oncology10.1007/s11060-010-0152-62010100151-64The CXCR4 antagonist AMD3100 suppresses hypoxia-mediated growth hormone production in GH3 rat pituitary adenoma cellsD. Yoshida, K Koketshu, R. Nomura, A. Teramotohttp://link.springer.com/content/pdf/10.1007/s11060-010-0152-6.pdf, http://link.springer.com/article/10.1007/s11060-010-0152-6/fulltext.html, http://link.springer.com/content/pdf/10.1007/s11060-010-0152-6
Yearbook of Oncology10.1016/s1040-1741(10)79556-720102010128-129Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100R.J. Arcecihttps://api.elsevier.com/content/article/PII:S1040174110795567?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1040174110795567?httpAccept=text/plain
Experimental Hematology10.1016/j.exphem.2008.10.0172009373402-415.e1Insights into the biology of mobilized hematopoietic stem/progenitor cells through innovative treatment schedules of the CXCR4 antagonist AMD3100Halvard Bonig, Doreen Chudziak, Greg Priestley, Thalia Papayannopoulouhttps://api.elsevier.com/content/article/PII:S0301472X08005109?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0301472X08005109?httpAccept=text/plain
Pharmacology & Therapeutics10.1016/j.pharmthera.2010.08.00920101283509-518Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobilâ„¢) and potential of other CXCR4 antagonists as stem cell mobilizersErik De Clercqhttps://api.elsevier.com/content/article/PII:S0163725810001683?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0163725810001683?httpAccept=text/plain